New combo therapy targets hard-to-treat lung cancer in chinese patients

NCT ID NCT05374603

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests whether combining two drugs, savolitinib and durvalumab, can help control advanced lung cancer in people whose tumors have a specific genetic change called MET alteration. About 47 adults in China with non-small cell lung cancer that has spread will receive the combination. The main goal is to see how long the cancer stays under control without growing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research Site

    Beijing, 100021, China

  • Research Site

    Beijing, 100039, China

  • Research Site

    Beijing, CN-100730, China

  • Research Site

    Changsha, 410011, China

  • Research Site

    Chongqing, 400010, China

  • Research Site

    Hangzhou, 310003, China

  • Research Site

    Hangzhou, 310009, China

  • Research Site

    Jinan, 250021, China

  • Research Site

    Kunming, 650118, China

  • Research Site

    Nanchang, 330006, China

  • Research Site

    Ningbo, 315100, China

  • Research Site

    Shanghai, 200030, China

  • Research Site

    Wenzhou, 325000, China

  • Research Site

    Wuhan, 430022, China

  • Research Site

    Wuhan, 430030, China

  • Research Site

    Zhengzhou, 450000, China